Public health expertise / Putting our expertise and skills at the service of public health by producing the strongest evidence Mon, 20 Dec 2021 22:19:09 +0000 fr-FR hourly 1 https://wordpress.org/?v=6.6.2 /wp-content/uploads/2021/09/favicon9-50x50.png Public health expertise / 32 32 Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program /2021/12/20/cost-effectiveness-analysis-of-alternative-colon-cancer-screening-strategies-in-the-context-of-the-french-national-screening-program/ /2021/12/20/cost-effectiveness-analysis-of-alternative-colon-cancer-screening-strategies-in-the-context-of-the-french-national-screening-program/#respond Mon, 20 Dec 2021 22:16:32 +0000 http://phexpert.cluster015.ovh.net/?p=1364 […]]]> Barré, S., H. Leleu, R. Benamouzig, J. C. Saurin, A. Vimont, S. Taleb, and F. De Bels. 2020. ‘Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program’, Therap Adv Gastroenterol, 13: 1756284820953364.

]]>
/2021/12/20/cost-effectiveness-analysis-of-alternative-colon-cancer-screening-strategies-in-the-context-of-the-french-national-screening-program/feed/ 0
SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia /2021/12/20/safeheart-risk-equation-and-cholesterol-year-score-are-powerful-predictors-of-cardiovascular-events-in-french-patients-with-familial-hypercholesterolemia/ /2021/12/20/safeheart-risk-equation-and-cholesterol-year-score-are-powerful-predictors-of-cardiovascular-events-in-french-patients-with-familial-hypercholesterolemia/#respond Mon, 20 Dec 2021 22:14:51 +0000 http://phexpert.cluster015.ovh.net/?p=1361 […]]]> Gallo, A., S. Charriere, A. Vimont, M. J. Chapman, D. Angoulvant, F. Boccara, B. Cariou, V. Carreau, A. Carrié, E. Bruckert, and S. Béliard. 2020. ‘SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia’, Atherosclerosis, 306: 41-49.

]]>
/2021/12/20/safeheart-risk-equation-and-cholesterol-year-score-are-powerful-predictors-of-cardiovascular-events-in-french-patients-with-familial-hypercholesterolemia/feed/ 0
A stochastic agent-based model of the SARS-CoV-2 epidemic in France /2021/12/20/a-stochastic-agent-based-model-of-the-sars-cov-2-epidemic-in-france/ /2021/12/20/a-stochastic-agent-based-model-of-the-sars-cov-2-epidemic-in-france/#respond Mon, 20 Dec 2021 22:12:50 +0000 http://phexpert.cluster015.ovh.net/?p=1358 […]]]> Hoertel, N., M. Blachier, C. Blanco, M. Olfson, M. Massetti, M. S. Rico, F. Limosin, and H. Leleu. 2020. ‘A stochastic agent-based model of the SARS-CoV-2 epidemic in France’, Nat Med, 26: 1417-21.

]]>
/2021/12/20/a-stochastic-agent-based-model-of-the-sars-cov-2-epidemic-in-france/feed/ 0
Cost-effectiveness of Lutetium [(177)Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France /2021/12/20/cost-effectiveness-of-lutetium-177lu-oxodotreotide-versus-best-supportive-care-with-octreotide-in-patients-with-midgut-neuroendocrine-tumors-in-france/ /2021/12/20/cost-effectiveness-of-lutetium-177lu-oxodotreotide-versus-best-supportive-care-with-octreotide-in-patients-with-midgut-neuroendocrine-tumors-in-france/#respond Mon, 20 Dec 2021 22:10:32 +0000 http://phexpert.cluster015.ovh.net/?p=1355 […]]]> Leeuwenkamp, O., J. Smith-Palmer, R. Ortiz, A. Werner, W. Valentine, M. Blachier, and T. Walter. 2020. ‘Cost-effectiveness of Lutetium [(177)Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France’, J Med Econ, 23: 1534-41.

]]>
/2021/12/20/cost-effectiveness-of-lutetium-177lu-oxodotreotide-versus-best-supportive-care-with-octreotide-in-patients-with-midgut-neuroendocrine-tumors-in-france/feed/ 0
Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals /2021/12/20/cost-effectiveness-analysis-of-alternative-colorectal-cancer-screening-strategies-in-high-risk-individuals/ /2021/12/20/cost-effectiveness-analysis-of-alternative-colorectal-cancer-screening-strategies-in-high-risk-individuals/#respond Mon, 20 Dec 2021 22:07:34 +0000 http://phexpert.cluster015.ovh.net/?p=1352 […]]]> Benamouzig, R., S. Barré, J. C. Saurin, H. Leleu, A. Vimont, S. Taleb, and F. De Bels. 2021. ‘Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals’, Therap Adv Gastroenterol, 14: 17562848211002359.

]]>
/2021/12/20/cost-effectiveness-analysis-of-alternative-colorectal-cancer-screening-strategies-in-high-risk-individuals/feed/ 0
Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals /2021/12/20/dalbavancin-in-real-life-economic-impact-of-prescription-timing-in-french-hospitals/ /2021/12/20/dalbavancin-in-real-life-economic-impact-of-prescription-timing-in-french-hospitals/#respond Mon, 20 Dec 2021 22:05:43 +0000 http://phexpert.cluster015.ovh.net/?p=1349 […]]]> Béraud, G., J. C. Maupetit, A. Darras, A. Vimont, and M. Blachier. 2021. ‘Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals’, Infect Dis Ther.

]]>
/2021/12/20/dalbavancin-in-real-life-economic-impact-of-prescription-timing-in-french-hospitals/feed/ 0
The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia /2021/12/20/the-added-value-of-coronary-calcium-score-in-predicting-cardiovascular-events-in-familial-hypercholesterolemia/ /2021/12/20/the-added-value-of-coronary-calcium-score-in-predicting-cardiovascular-events-in-familial-hypercholesterolemia/#respond Mon, 20 Dec 2021 22:02:47 +0000 http://phexpert.cluster015.ovh.net/?p=1346 […]]]> Gallo, A., L. Pérez de Isla, S. Charrière, A. Vimont, R. Alonso, O. Muñiz-Grijalvo, J. L. Díaz-Díaz, D. Zambón, P. Moulin, E. Bruckert, P. Mata, and S. Béliard. 2021. ‘The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia’, JACC Cardiovasc Imaging, 14: 2414-24.

]]>
/2021/12/20/the-added-value-of-coronary-calcium-score-in-predicting-cardiovascular-events-in-familial-hypercholesterolemia/feed/ 0
Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database /2021/12/20/epidemiology-and-disease-burden-of-sickle-cell-disease-in-france-a-descriptive-study-based-on-a-french-nationwide-claim-database/ /2021/12/20/epidemiology-and-disease-burden-of-sickle-cell-disease-in-france-a-descriptive-study-based-on-a-french-nationwide-claim-database/#respond Mon, 20 Dec 2021 22:00:20 +0000 http://phexpert.cluster015.ovh.net/?p=1343 […]]]> Leleu, H., J. B. Arlet, A. Habibi, M. Etienne-Julan, M. Khellaf, Y. Adjibi, F. Pirenne, M. Pitel, A. Granghaud, C. Sinniah, M. De Montalembert, and F. Galacteros. 2021. ‘Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database’, PLoS One, 16: e0253986.

]]>
/2021/12/20/epidemiology-and-disease-burden-of-sickle-cell-disease-in-france-a-descriptive-study-based-on-a-french-nationwide-claim-database/feed/ 0
Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France /2021/12/20/machine-learning-versus-regression-modelling-in-predicting-individual-healthcare-costs-from-a-representative-sample-of-the-nationwide-claims-database-in-france/ /2021/12/20/machine-learning-versus-regression-modelling-in-predicting-individual-healthcare-costs-from-a-representative-sample-of-the-nationwide-claims-database-in-france/#respond Mon, 20 Dec 2021 21:44:13 +0000 http://phexpert.cluster015.ovh.net/?p=1335 […]]]> Vimont, A., H. Leleu, and I. Durand-Zaleski. 2021. ‘Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France’, Eur J Health Econ.

]]>
/2021/12/20/machine-learning-versus-regression-modelling-in-predicting-individual-healthcare-costs-from-a-representative-sample-of-the-nationwide-claims-database-in-france/feed/ 0
A survey of patient blood management for patients undergoing cardiac surgery in nine European countrie /2021/09/07/a-survey-of-patient-blood-management-for-patients-undergoing-cardiac-surgery-in-nine-european-countrie-3/ /2021/09/07/a-survey-of-patient-blood-management-for-patients-undergoing-cardiac-surgery-in-nine-european-countrie-3/#comments Tue, 07 Sep 2021 09:53:22 +0000 http://phexpert.cluster015.ovh.net/?p=1222 […]]]> Klein A, Agarwal S, Cholley B, Fassl J, Griffin M, Kaakinen T, Mzallassi Z, Paulus P, Rex S, Siegemund M, van Saet A. A survey of patient blood management for patients undergoing cardiac surgery…

]]>
/2021/09/07/a-survey-of-patient-blood-management-for-patients-undergoing-cardiac-surgery-in-nine-european-countrie-3/feed/ 2
This XML file does not appear to have any style information associated with it. The document tree is shown below.
<rss xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" version="2.0">
<channel>
<title>Public health expertise</title>
<atom:link href="/feed/" rel="self" type="application/rss+xml"/>
<link>/</link>
<description>Putting our expertise and skills at the service of public health by producing the strongest evidence</description>
<lastBuildDate>Mon, 20 Dec 2021 22:19:09 +0000</lastBuildDate>
<language>fr-FR</language>
<sy:updatePeriod> hourly </sy:updatePeriod>
<sy:updateFrequency> 1 </sy:updateFrequency>
<generator>https://wordpress.org/?v=6.6.2</generator>
<image>
<url>/wp-content/uploads/2021/09/favicon9-50x50.png</url>
<title>Public health expertise</title>
<link>/</link>
<width>32</width>
<height>32</height>
</image>
<item>
<title>Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program</title>
<link>/2021/12/20/cost-effectiveness-analysis-of-alternative-colon-cancer-screening-strategies-in-the-context-of-the-french-national-screening-program/</link>
<comments>/2021/12/20/cost-effectiveness-analysis-of-alternative-colon-cancer-screening-strategies-in-the-context-of-the-french-national-screening-program/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 22:16:32 +0000</pubDate>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1364</guid>
<description>
<![CDATA[ Barré, S., H. Leleu, R. Benamouzig, J. C. Saurin, A. Vimont, S. Taleb, and F. De Bels. 2020. &#8216;Cost-effectiveness analysis of alternative colon cancer screening strategies<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Barré, S., H. Leleu, R. Benamouzig, J. C. Saurin, A. Vimont, S. Taleb, and F. De Bels. 2020. &lsquo;Cost-effectiveness analysis of alternative colon cancer screening strategies in the context of the French national screening program&rsquo;, Therap Adv Gastroenterol, 13: 1756284820953364.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/cost-effectiveness-analysis-of-alternative-colon-cancer-screening-strategies-in-the-context-of-the-french-national-screening-program/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia</title>
<link>/2021/12/20/safeheart-risk-equation-and-cholesterol-year-score-are-powerful-predictors-of-cardiovascular-events-in-french-patients-with-familial-hypercholesterolemia/</link>
<comments>/2021/12/20/safeheart-risk-equation-and-cholesterol-year-score-are-powerful-predictors-of-cardiovascular-events-in-french-patients-with-familial-hypercholesterolemia/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 22:14:51 +0000</pubDate>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1361</guid>
<description>
<![CDATA[ Gallo, A., S. Charriere, A. Vimont, M. J. Chapman, D. Angoulvant, F. Boccara, B. Cariou, V. Carreau, A. Carrié, E. Bruckert, and S. Béliard. 2020. &#8216;SAFEHEART<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Gallo, A., S. Charriere, A. Vimont, M. J. Chapman, D. Angoulvant, F. Boccara, B. Cariou, V. Carreau, A. Carrié, E. Bruckert, and S. Béliard. 2020. &lsquo;SAFEHEART risk-equation and cholesterol-year-score are powerful predictors of cardiovascular events in French patients with familial hypercholesterolemia&rsquo;, Atherosclerosis, 306: 41-49.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/safeheart-risk-equation-and-cholesterol-year-score-are-powerful-predictors-of-cardiovascular-events-in-french-patients-with-familial-hypercholesterolemia/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>A stochastic agent-based model of the SARS-CoV-2 epidemic in France</title>
<link>/2021/12/20/a-stochastic-agent-based-model-of-the-sars-cov-2-epidemic-in-france/</link>
<comments>/2021/12/20/a-stochastic-agent-based-model-of-the-sars-cov-2-epidemic-in-france/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 22:12:50 +0000</pubDate>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1358</guid>
<description>
<![CDATA[ Hoertel, N., M. Blachier, C. Blanco, M. Olfson, M. Massetti, M. S. Rico, F. Limosin, and H. Leleu. 2020. &#8216;A stochastic agent-based model of the SARS-CoV-2<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Hoertel, N., M. Blachier, C. Blanco, M. Olfson, M. Massetti, M. S. Rico, F. Limosin, and H. Leleu. 2020. &lsquo;A stochastic agent-based model of the SARS-CoV-2 epidemic in France&rsquo;, Nat Med, 26: 1417-21.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/a-stochastic-agent-based-model-of-the-sars-cov-2-epidemic-in-france/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>Cost-effectiveness of Lutetium [(177)Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France</title>
<link>/2021/12/20/cost-effectiveness-of-lutetium-177lu-oxodotreotide-versus-best-supportive-care-with-octreotide-in-patients-with-midgut-neuroendocrine-tumors-in-france/</link>
<comments>/2021/12/20/cost-effectiveness-of-lutetium-177lu-oxodotreotide-versus-best-supportive-care-with-octreotide-in-patients-with-midgut-neuroendocrine-tumors-in-france/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 22:10:32 +0000</pubDate>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1355</guid>
<description>
<![CDATA[ Leeuwenkamp, O., J. Smith-Palmer, R. Ortiz, A. Werner, W. Valentine, M. Blachier, and T. Walter. 2020. &#8216;Cost-effectiveness of Lutetium [(177)Lu] oxodotreotide versus best supportive care with<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Leeuwenkamp, O., J. Smith-Palmer, R. Ortiz, A. Werner, W. Valentine, M. Blachier, and T. Walter. 2020. &lsquo;Cost-effectiveness of Lutetium [(177)Lu] oxodotreotide versus best supportive care with octreotide in patients with midgut neuroendocrine tumors in France&rsquo;, J Med Econ, 23: 1534-41.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/cost-effectiveness-of-lutetium-177lu-oxodotreotide-versus-best-supportive-care-with-octreotide-in-patients-with-midgut-neuroendocrine-tumors-in-france/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals</title>
<link>/2021/12/20/cost-effectiveness-analysis-of-alternative-colorectal-cancer-screening-strategies-in-high-risk-individuals/</link>
<comments>/2021/12/20/cost-effectiveness-analysis-of-alternative-colorectal-cancer-screening-strategies-in-high-risk-individuals/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 22:07:34 +0000</pubDate>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1352</guid>
<description>
<![CDATA[ Benamouzig, R., S. Barré, J. C. Saurin, H. Leleu, A. Vimont, S. Taleb, and F. De Bels. 2021. &#8216;Cost-effectiveness analysis of alternative colorectal cancer screening strategies<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Benamouzig, R., S. Barré, J. C. Saurin, H. Leleu, A. Vimont, S. Taleb, and F. De Bels. 2021. &lsquo;Cost-effectiveness analysis of alternative colorectal cancer screening strategies in high-risk individuals&rsquo;, Therap Adv Gastroenterol, 14: 17562848211002359.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/cost-effectiveness-analysis-of-alternative-colorectal-cancer-screening-strategies-in-high-risk-individuals/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals</title>
<link>/2021/12/20/dalbavancin-in-real-life-economic-impact-of-prescription-timing-in-french-hospitals/</link>
<comments>/2021/12/20/dalbavancin-in-real-life-economic-impact-of-prescription-timing-in-french-hospitals/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 22:05:43 +0000</pubDate>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1349</guid>
<description>
<![CDATA[ Béraud, G., J. C. Maupetit, A. Darras, A. Vimont, and M. Blachier. 2021. &#8216;Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals&#8217;, Infect<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Béraud, G., J. C. Maupetit, A. Darras, A. Vimont, and M. Blachier. 2021. &lsquo;Dalbavancin in Real Life: Economic Impact of Prescription Timing in French Hospitals&rsquo;, Infect Dis Ther.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/dalbavancin-in-real-life-economic-impact-of-prescription-timing-in-french-hospitals/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia</title>
<link>/2021/12/20/the-added-value-of-coronary-calcium-score-in-predicting-cardiovascular-events-in-familial-hypercholesterolemia/</link>
<comments>/2021/12/20/the-added-value-of-coronary-calcium-score-in-predicting-cardiovascular-events-in-familial-hypercholesterolemia/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 22:02:47 +0000</pubDate>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1346</guid>
<description>
<![CDATA[ Gallo, A., L. Pérez de Isla, S. Charrière, A. Vimont, R. Alonso, O. Muñiz-Grijalvo, J. L. Díaz-Díaz, D. Zambón, P. Moulin, E. Bruckert, P. Mata, and<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Gallo, A., L. Pérez de Isla, S. Charrière, A. Vimont, R. Alonso, O. Muñiz-Grijalvo, J. L. Díaz-Díaz, D. Zambón, P. Moulin, E. Bruckert, P. Mata, and S. Béliard. 2021. &lsquo;The Added Value of Coronary Calcium Score in Predicting Cardiovascular Events in Familial Hypercholesterolemia&rsquo;, JACC Cardiovasc Imaging, 14: 2414-24.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/the-added-value-of-coronary-calcium-score-in-predicting-cardiovascular-events-in-familial-hypercholesterolemia/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database</title>
<link>/2021/12/20/epidemiology-and-disease-burden-of-sickle-cell-disease-in-france-a-descriptive-study-based-on-a-french-nationwide-claim-database/</link>
<comments>/2021/12/20/epidemiology-and-disease-burden-of-sickle-cell-disease-in-france-a-descriptive-study-based-on-a-french-nationwide-claim-database/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 22:00:20 +0000</pubDate>
<category>
<![CDATA[ News ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1343</guid>
<description>
<![CDATA[ Leleu, H., J. B. Arlet, A. Habibi, M. Etienne-Julan, M. Khellaf, Y. Adjibi, F. Pirenne, M. Pitel, A. Granghaud, C. Sinniah, M. De Montalembert, and F.<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Leleu, H., J. B. Arlet, A. Habibi, M. Etienne-Julan, M. Khellaf, Y. Adjibi, F. Pirenne, M. Pitel, A. Granghaud, C. Sinniah, M. De Montalembert, and F. Galacteros. 2021. &lsquo;Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database&rsquo;, PLoS One, 16: e0253986.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/epidemiology-and-disease-burden-of-sickle-cell-disease-in-france-a-descriptive-study-based-on-a-french-nationwide-claim-database/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France</title>
<link>/2021/12/20/machine-learning-versus-regression-modelling-in-predicting-individual-healthcare-costs-from-a-representative-sample-of-the-nationwide-claims-database-in-france/</link>
<comments>/2021/12/20/machine-learning-versus-regression-modelling-in-predicting-individual-healthcare-costs-from-a-representative-sample-of-the-nationwide-claims-database-in-france/#respond</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Mon, 20 Dec 2021 21:44:13 +0000</pubDate>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1335</guid>
<description>
<![CDATA[ Vimont, A., H. Leleu, and I. Durand-Zaleski. 2021. &#8216;Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Vimont, A., H. Leleu, and I. Durand-Zaleski. 2021. &lsquo;Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France&rsquo;, Eur J Health Econ.</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/12/20/machine-learning-versus-regression-modelling-in-predicting-individual-healthcare-costs-from-a-representative-sample-of-the-nationwide-claims-database-in-france/feed/</wfw:commentRss>
<slash:comments>0</slash:comments>
</item>
<item>
<title>A survey of patient blood management for patients undergoing cardiac surgery in nine European countrie</title>
<link>/2021/09/07/a-survey-of-patient-blood-management-for-patients-undergoing-cardiac-surgery-in-nine-european-countrie-3/</link>
<comments>/2021/09/07/a-survey-of-patient-blood-management-for-patients-undergoing-cardiac-surgery-in-nine-european-countrie-3/#comments</comments>
<dc:creator>
<![CDATA[ Yann Legoff ]]>
</dc:creator>
<pubDate>Tue, 07 Sep 2021 09:53:22 +0000</pubDate>
<category>
<![CDATA[ Non classé ]]>
</category>
<category>
<![CDATA[ Publications ]]>
</category>
<guid isPermaLink="false">http://phexpert.cluster015.ovh.net/?p=1222</guid>
<description>
<![CDATA[ Klein A, Agarwal S, Cholley B, Fassl J, Griffin M, Kaakinen T, Mzallassi Z, Paulus P, Rex S, Siegemund M, van Saet A. A survey of<span class="excerpt-hellip"> […]</span> ]]>
</description>
<content:encoded>
<![CDATA[ <p>Klein A, Agarwal S, Cholley B, Fassl J, Griffin M, Kaakinen T, Mzallassi Z, Paulus P, Rex S, Siegemund M, van Saet A. A survey of patient blood management for patients undergoing cardiac surgery…</p> ]]>
</content:encoded>
<wfw:commentRss>/2021/09/07/a-survey-of-patient-blood-management-for-patients-undergoing-cardiac-surgery-in-nine-european-countrie-3/feed/</wfw:commentRss>
<slash:comments>2</slash:comments>
</item>
</channel>
</rss>